Italian Cancer Institute Foundation launches NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events

The IRCCS National Cancer Institute Foundation (Fondazione IRCCS Istituto Nazionale dei Tumori, Milano) is starting a new clinical trial of NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events.

The lacking adherence to guidelines on prevention and treatment of different chemotherapy, targeted therapy, and immunotherapy induced toxicities is the reason why there are a potential incidence and duration increase of adverse events. It is clear the need of a collateral effect early recognition for an adequate clinical management and for limiting their intensity and duration.

There is the need for a multicentre randomized clinical study in specific therapeutical settings (chemotherapy, target therapy, immunotherapy) assessing the impact of planned and ongoing patients' monitoring by nurses.

The NICSO study foresees patient enrolment that is in adjuvant chemotherapy for breast cancer, colon, and lung; that is in chemotherapy or immunotherapy or with targeted therapy. Moreover, this working assesses toxicity differences (but also of QoL, number of PS access or non-planned medical examinations, number of hospitalization and number of recovery days) in patients that carried out a toxicity prevention and cure standard therapy in comparison with the standard assessment to which is added a periodic nursing phone intervention

The inclusion parameters are:

• Patients aged >18.
• Solid cancer histological diagnosis on treatment with one of the listed medicines, defined by treatment type:
• Adjuvant chemotherapy
• First line oral target therapy
• Immunotherapy:

The full list can be viewed at the link below.

The clinical trial started in March 1, 2018 and will continue throughout December 31, 2021.

The contacts and locations are the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

The IRCCS National Cancer Institute Foundation (previously called the Vittorio Emanuele III Institute for the study and treatment of cancer, today simply called the National Cancer Institute and abbreviated as INT), is a Milanese public hospital dedicated exclusively to the treatment of cancer, both from a clinical and research point of view.

For more details: https://ichgcp.net/clinical-trials-registry/NCT04726020